Authors
Rafael R De Assis, Aarti Jain, Rie Nakajima, Algis Jasinskas, Jiin Felgner, Joshua M Obiero, Philip J Norris, Mars Stone, Graham Simmons, Anil Bagri, Johannes Irsch, Martin Schreiber, Andreas Buser, Andreas Holbro, Manuel Battegay, Philip Hosimer, Charles Noesen, Oluwasanmi Adenaiye, Sheldon Tai, Filbert Hong, Donald K Milton, D Huw Davies, Paul Contestable, Laurence M Corash, Michael P Busch, Philip L Felgner, Saahir Khan
Publication date
2021/1/4
Journal
Nature communications
Volume
12
Issue
1
Pages
6
Publisher
Nature Publishing Group UK
Description
The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates near complete discrimination of these two groups, with improved performance from …
Scholar articles
RR De Assis, A Jain, R Nakajima, A Jasinskas… - Nature communications, 2021